Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

August 29, 2023

Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.

August 29, 2023

Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.

August 22, 2023

Antonia Sepulveda, MD, PhD, an expert on NSCLC, outlines discrepancies in molecular testing between academic and community settings.

August 22, 2023

Focused discussion on tissue testing and the effect of turnaround time on NSCLC treatment and molecular testing strategies.

August 15, 2023

Expert oncologists compare the logistics and sensitivities of liquid and tissue biopsies in the treatment of non–small cell lung cancer.

August 15, 2023

A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.

August 11, 2023

Yasser Mohamed Ali Ged, MBBS, highlights the early efficacy seen in patients with renal cell carcinoma with BAP1 mutations and next steps for the ORCHID trial.

July 26, 2023

Robert Albert Anders, MD, PhD, discusses the rationale for developing CCR4 antagonists for use in patients with advanced cancers, including lymphoma and non–small cell lung cancer.

July 21, 2023

Closing out their discussion on uncommon EGFR mutations in non–small cell lung cancer, Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, consider how the treatment paradigm will continue to evolve.

July 21, 2023

Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, reflect on their experience managing real-world patients with uncommon EGFR mutations in non–small cell lung cancer.

July 18, 2023

Yasser Mohamed Ali Ged, MBBS, discusses the background of launching the phase 2 ORCHID trial evaluating olaparib monotherapy in patients with metastatic renal cell carcinoma harboring BAP1 or other DNA repair gene mutations.

July 16, 2023

Joseph Christopher Murray, MD, discusses the role of prognostic markers in non–small cell lung cancer and how data from the EMPOWER trials will guide future directions in the space.

July 14, 2023

Focused discussion on uncommon EGFR mutations in non–small cell lung cancer and concurrent treatment options in this setting.

July 14, 2023

Experts Benjamin Levy, MD, and Estelamari Rodriguez, MD, MPH, highlight current understandings of EGFR mutation classifications in the context of non–small cell lung cancer.

July 13, 2023

As antibody-drug conjugates become an established part of the lung cancer treatment paradigm, identifying which patients will benefit the most from treatment with these highly specific agents remains a challenge for clinicians.

July 11, 2023

Benjamin Philip Levy, MD, discusses the relationship between upfront next-generation sequencing and survival outcomes in non–small cell lung cancer.

June 30, 2023

Expert oncologists reflect on the current state of molecular testing in patients with non–small cell lung cancer and how it has impacted treatment pathways.

June 29, 2023

Vincent K. Lam, MD, discusses findings from a study profiling the tumor immune microenvironment in patients with ALK fusion–positive lung cancer and potential future directions for this research.

June 11, 2023

Gilteritinib led to a 48% reduction in disease recurrence for patients with FLT3-ITD–mutant acute myeloid leukemia and detectable minimal residual disease pre and post hematopoietic stem cell transplant compared with placebo, highlighting a role for treatment in this subgroup of patients.

June 11, 2023

Mark J. Levis, MD, PhD, discusses data from the phase 3 BMT CTN 1506/MORPHO trial of gilteritinib as maintenance therapy following allogeneic stem cell transplant in patients With FLT3-ITD–positive acute myeloid leukemia.